These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 34080116)

  • 1. Targeting cellular batteries for the therapy of neurological diseases.
    Arora A; Behl T; Sehgal A; Singh S; Sharma N; Mathew B; Bungau S
    Environ Sci Pollut Res Int; 2021 Aug; 28(31):41517-41532. PubMed ID: 34080116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Connecting the dots between mitochondrial dysfunction and Parkinson's disorder: focus mitochondria-targeting therapeutic paradigm in mitigating the disease severity.
    Kaur I; Behl T; Sehgal A; Singh S; Sharma N; Aleya L; Bungau S
    Environ Sci Pollut Res Int; 2021 Jul; 28(28):37060-37081. PubMed ID: 34053042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial dysfunction in progressive supranuclear palsy.
    Albers DS; Beal MF
    Neurochem Int; 2002 May; 40(6):559-64. PubMed ID: 11850113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial dysfunction and oxidative stress in Alzheimer's disease, and Parkinson's disease, Huntington's disease and Amyotrophic Lateral Sclerosis -An updated review.
    Alqahtani T; Deore SL; Kide AA; Shende BA; Sharma R; Dadarao Chakole R; Nemade LS; Kishor Kale N; Borah S; Shrikant Deokar S; Behera A; Dhawal Bhandari D; Gaikwad N; Kalam Azad A; Ghosh A
    Mitochondrion; 2023 Jul; 71():83-92. PubMed ID: 37269968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders.
    Olesen MA; Villavicencio-Tejo F; Quintanilla RA
    Transl Neurodegener; 2022 Jul; 11(1):36. PubMed ID: 35787292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Mitochondrial Defects to Increase Longevity in Animal Models of Neurodegenerative Diseases.
    Casajus Pelegay E; Puzzo F; Yilmazer A; Cagin U
    Adv Exp Med Biol; 2019; 1134():89-110. PubMed ID: 30919333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial dysfunction and neurological disorders: A narrative review and treatment overview.
    Alshial EE; Abdulghaney MI; Wadan AS; Abdellatif MA; Ramadan NE; Suleiman AM; Waheed N; Abdellatif M; Mohammed HS
    Life Sci; 2023 Dec; 334():122257. PubMed ID: 37949207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Therapeutic Potential of Mitochondria Transplantation Therapy in Neurodegenerative and Neurovascular Disorders.
    Khan MM; Paez HG; Pitzer CR; Alway SE
    Curr Neuropharmacol; 2023; 21(5):1100-1116. PubMed ID: 36089791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging concepts of mitochondrial dysfunction in Parkinson's disease progression: Pathogenic and therapeutic implications.
    Rani L; Mondal AC
    Mitochondrion; 2020 Jan; 50():25-34. PubMed ID: 31654753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial biogenesis: pharmacological approaches.
    Valero T
    Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial dysfunctions in neurodegenerative diseases: relevance to Alzheimer's disease.
    Hroudová J; Singh N; Fišar Z
    Biomed Res Int; 2014; 2014():175062. PubMed ID: 24900954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Insight Into Mitochondrial Dysfunction and its Implications in Neurological Diseases.
    Waseem R; Shamsi A; Kazim SN; Islam A
    Curr Drug Targets; 2021; 22(14):1585-1595. PubMed ID: 33390128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approaches to Mitigate Mitochondrial Dysfunction in Sensorineural Hearing Loss.
    Okur MN; Djalilian HR
    Ann Biomed Eng; 2022 Dec; 50(12):1762-1770. PubMed ID: 36369597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fighting Parkinson's disease: The return of the mitochondria.
    Zambrano K; Barba D; Castillo K; Noboa L; Argueta-Zamora D; Robayo P; Arizaga E; Caicedo A; Gavilanes AWD
    Mitochondrion; 2022 May; 64():34-44. PubMed ID: 35218960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial permeability transition pore: a promising target for the treatment of Parkinson's disease.
    Rasheed MZ; Tabassum H; Parvez S
    Protoplasma; 2017 Jan; 254(1):33-42. PubMed ID: 26825389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The multi-faceted role of mitochondria in the pathology of Parkinson's disease.
    Trinh D; Israwi AR; Arathoon LR; Gleave JA; Nash JE
    J Neurochem; 2021 Mar; 156(6):715-752. PubMed ID: 33616931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial biology and Parkinson's disease.
    Perier C; Vila M
    Cold Spring Harb Perspect Med; 2012 Feb; 2(2):a009332. PubMed ID: 22355801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of Mitochondrial Dysfunction in the Pathogenesis of Parkinson's Disease.
    Blagov A; Postnov A; Sukhorukov V; Popov M; Uzokov J; Orekhov A
    Front Biosci (Landmark Ed); 2024 Jan; 29(1):36. PubMed ID: 38287806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative Stress: A Key Modulator in Neurodegenerative Diseases.
    Singh A; Kukreti R; Saso L; Kukreti S
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31013638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting calcium homeostasis and impaired inter-organelle crosstalk as a potential therapeutic approach in Parkinson's disease.
    Kaur S; Sehrawat A; Mastana SS; Kandimalla R; Sharma PK; Bhatti GK; Bhatti JS
    Life Sci; 2023 Oct; 330():121995. PubMed ID: 37541578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.